ATE147975T1 - Partikelförmiges vektor und pharmazeutische zusammensetzung die diese enthält - Google Patents

Partikelförmiges vektor und pharmazeutische zusammensetzung die diese enthält

Info

Publication number
ATE147975T1
ATE147975T1 AT94913676T AT94913676T ATE147975T1 AT E147975 T1 ATE147975 T1 AT E147975T1 AT 94913676 T AT94913676 T AT 94913676T AT 94913676 T AT94913676 T AT 94913676T AT E147975 T1 ATE147975 T1 AT E147975T1
Authority
AT
Austria
Prior art keywords
pct
pharmaceutical composition
composition containing
particulate vector
same
Prior art date
Application number
AT94913676T
Other languages
English (en)
Inventor
Pierre Perrin
Daniel Samain
Nathalie Castignolles
Original Assignee
Pasteur Institut
Biovector Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Biovector Therapeutics Sa filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE147975T1 publication Critical patent/ATE147975T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2991—Coated

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT94913676T 1993-04-21 1994-04-21 Partikelförmiges vektor und pharmazeutische zusammensetzung die diese enthält ATE147975T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9304698A FR2704145B1 (fr) 1993-04-21 1993-04-21 Vecteur particulaire et composition pharmaceutique le contenant.

Publications (1)

Publication Number Publication Date
ATE147975T1 true ATE147975T1 (de) 1997-02-15

Family

ID=9446283

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94913676T ATE147975T1 (de) 1993-04-21 1994-04-21 Partikelförmiges vektor und pharmazeutische zusammensetzung die diese enthält

Country Status (8)

Country Link
US (1) US5891475A (de)
EP (1) EP0696191B1 (de)
JP (1) JPH08508990A (de)
AT (1) ATE147975T1 (de)
CA (1) CA2161121A1 (de)
DE (1) DE69401581T2 (de)
FR (1) FR2704145B1 (de)
WO (1) WO1994023701A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2723849B1 (fr) * 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
FR2771929B1 (fr) * 1997-12-09 2001-02-23 Biovector Therapeutics Utilisation dans une composition pharmaceutique pour l'administration par voie nasale de particules hydrophiles pour la delivrance d'agents actifs au systeme nerveux central
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
EP1143934B1 (de) * 1999-01-13 2003-06-04 Johns Hopkins University School of Medicine Genetische immunisierung mit gleichzeitiger verabreichung von nukleinsäuren und zytokinen
EP2028190A1 (de) 1999-04-02 2009-02-25 Corixa Corporation Verbindungen und Verfahren für Therapie und Diagnose von Lungenkrebs
US6673601B1 (en) 1999-04-15 2004-01-06 Institut Pasteur Chimeric lyssavirus nucleic acids and polypeptides
EP1721982B1 (de) 1999-04-15 2013-04-10 Boehringer Ingelheim Vetmedica GmbH Chimäre Nukleinsäuren und Polypeptide aus Iyssavirus
KR100919916B1 (ko) 2000-02-23 2009-10-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 종양 특이적 동물 단백질
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7238672B1 (en) 2000-04-17 2007-07-03 Institut Pasteur Chimeric lyssavirus nucleic acids and polypeptides
US20030175700A1 (en) 2000-04-21 2003-09-18 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
EP1276468A1 (de) * 2000-04-26 2003-01-22 Biovector Therapeutics S.A. Verwendung teilchenförmiger vektoren in der immunomodulation
FR2808194B1 (fr) * 2000-04-26 2004-05-07 Biovector Therapeutics Utilisation de particules hydrophiles portant ou non des ligands ioniques pour ameliorer les proprietes immunomodulatrices d'une substance autre qu'un antigene, et les compositions pharmaceutiques ainsi obtenues
SI1542732T1 (sl) 2000-06-20 2010-01-29 Corixa Corp Csc The United Sta Fuzijski proteini Mycobacterium tuberculosis
EP1319069B1 (de) 2000-06-28 2008-05-21 Corixa Corporation Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
EP1515982A4 (de) 2001-05-09 2005-10-26 Corixa Corp Zusammensetzungen und verfahren zur therapie und diagnose von prostatakrebs
DK1581119T3 (da) 2001-12-17 2013-05-13 Corixa Corp Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
US20060177495A1 (en) * 2001-12-21 2006-08-10 Christine Allen Polymer-lipid delivery vehicles
US20030235619A1 (en) * 2001-12-21 2003-12-25 Christine Allen Polymer-lipid delivery vehicles
ZA200505302B (en) 2003-01-06 2007-03-28 Corixa Corp Certain aminoalkyl glucosaminide phosphate compounds and their use
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US6809197B1 (en) 2003-06-11 2004-10-26 Mgp Ingredients, Inc. Emulsion stabilizing starch products
ES2586401T3 (es) 2003-06-16 2016-10-14 Ucb Pharma S.A. Anticuerpos específicos para la esclerostina y métodos para aumentar la mineralización ósea
CA2837748C (en) 2004-05-25 2016-03-08 Oregon Health And Science University Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
EP1786443B1 (de) 2004-07-19 2018-06-06 Celator Pharmaceuticals, Inc. Teilchenförmige konstrukte zur freisetzung von wirkstoffen
EP1797173B1 (de) 2004-10-08 2014-05-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Modulierung der replikationsrate durch verwendung von seltener verwendeten synonymen kodons
CA2602637A1 (en) 2005-03-31 2006-10-05 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
DK1877426T3 (da) 2005-04-29 2012-05-14 Glaxosmithkline Biolog Sa Fremgangsmåde til forebyggelse eller behandling af M Tuberculosis-infektion.
US8026354B2 (en) 2005-11-23 2011-09-27 Institut Pasteur Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use
EP1981905B1 (de) 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia-impfstoff
WO2007101681A1 (en) 2006-03-07 2007-09-13 Baxter International Inc Highly phosphorylated and sulfated recombinant factor ix
JP5524610B2 (ja) 2006-04-07 2014-06-18 ザ リサーチ ファウンデーション オブ ステイト ユニバーシティー オブ ニューヨーク トランスコバラミン受容体ポリペプチド、核酸およびその調節因子、ならびに細胞の増殖の調節ならびにガンおよびコバラミン欠損症の処置に使用する関連方法
US8110226B2 (en) 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
JP2011507919A (ja) 2007-12-27 2011-03-10 バクスター・インターナショナル・インコーポレイテッド 修飾第ｉｘ因子
ES2538007T3 (es) 2009-09-16 2015-06-16 Vaxart, Inc. Estrategia de inmunización para prevenir una infección por H1N1
CA2837651A1 (en) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
EP2776451B1 (de) 2011-11-11 2018-07-18 Fred Hutchinson Cancer Research Center Cyclin a1-gezielte t-zellen-immuntherapie gegen krebs
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
CA3091352A1 (en) 2018-02-21 2019-08-29 The University Of Montana Diaryl trehalose compounds and uses thereof
WO2019169313A1 (en) 2018-03-02 2019-09-06 The University Of Montana Immunogenic trehalose compounds and uses thereof
SG11202112870WA (en) 2019-05-23 2021-12-30 The Univ Of Montana Vaccine adjuvants based on tlr receptor ligands
BR112022002406A2 (pt) 2019-08-12 2022-07-19 Purinomia Biotech Inc Métodos e composições para promover e potencializar respostas imunes mediadas por célula t através do alvejamento de adcc de células que expressam cd39
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
WO2023057946A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2631826B1 (fr) * 1988-05-27 1992-06-19 Centre Nat Rech Scient Vecteur particulaire utile notamment pour le transport de molecules a activite biologique et procede pour sa preparation
JPH04503607A (ja) * 1989-02-24 1992-07-02 イムノセラピューティックス・インコーポレイテッド 固定化サイトカイン類
FR2677249B1 (fr) * 1991-06-04 1995-03-17 Biovecteurs As Vecteur particulaire biodegradable et procede de synthese.

Also Published As

Publication number Publication date
EP0696191B1 (de) 1997-01-22
EP0696191A1 (de) 1996-02-14
JPH08508990A (ja) 1996-09-24
DE69401581D1 (de) 1997-03-06
FR2704145B1 (fr) 1995-07-21
DE69401581T2 (de) 1997-08-21
WO1994023701A1 (fr) 1994-10-27
CA2161121A1 (fr) 1994-10-27
FR2704145A1 (fr) 1994-10-28
US5891475A (en) 1999-04-06

Similar Documents

Publication Publication Date Title
ATE147975T1 (de) Partikelförmiges vektor und pharmazeutische zusammensetzung die diese enthält
DE69115280T2 (de) Indolderivate, die die leukotrienbiosynthese hemmen.
DE68901955T2 (de) Insbesondere zum tragen von biologisch aktiven molekuelen geeignetes teilchenfoermiges vektorsystem und verfahren zu seiner herstellung.
TW286273B (de)
DE69413542T2 (de) Perhydroisoindolderivate als substanz p antagonisten
NO954320D0 (no) Lyosfærer omfattende gonadotropin
DE69414256T2 (de) Tropyl 7-azaindol-3-ylcarboxamide als antitussivum
PL317536A1 (en) Monoclonal antibody against cd 44v6
PL320167A1 (en) 2,2-dichloroalkanocarboxylic acids, method of obtaining them and therapeutic agents containing such compounds and their application in treating insulin immunity
ATE200672T1 (de) Alkoxyalkylcarbamate von imidazo(1,2-a)pyridinen
FI951511A0 (fi) IL-10:n käyttö insuliinista riippuvan diabetes mellituksen ennaltaestoon tai hoitoon
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
DE69319337D1 (en) Polyetheramidoamine hydrogele als heparinersatz
DK0649433T3 (da) Antigeniske regioner fra komplekser af tumorfrigivne partikler (TLP) og antistoffer mod sådanne.
AU1875395A (en) 4-amino derivatives of 5-substituted mycophenolic acid
DK0909182T3 (da) Fremgangsmåde til fremstilling af chloriner og bakteriochloriner indeholdende polyether
ATE279521T1 (de) Regulierende nukleinsaeuresequenzen und verwendungen
IL117734A0 (en) Beta-carbolines and pharmaceutical compositions containing them
RU95100512A (ru) Мазь для лечения кожных заболеваний
IT1231058B (it) Dispositivo perfezionato per l'azionamento di corpi alternativamente mobili quali ad esempio accessori o componenti di giocattoli o articoli promozionali.
MX9704978A (es) 5-aminopirazoles acilados y su empleo para la lucha contra las pestes animales.